FindTrial
Sign In

Atherogenic index of plasma to assess heart risk in patients with lichen planus

Atherogenic index of plasma as a novel marker for cardiovascular risk in lichen planus - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/108419
Enrollment
40
Registered
2026-04-15
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L43- Lichen planus

Interventions

Intervention1: Nil: Nil

Sponsors

Prasanna Kumar R G
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients clinically diagnosed with lichen planus Healthy volunteers matched for age, gender, BMI with lichen planus patients

Exclusion criteria

Exclusion criteria: Patients on treatment for lichen planus in lasst 4 weeks Overweight patients with bmi more than 25 Smokers or alcoholics Hypertension, Diabetes, Chronic liver disease, cardiovascular disease, thyroid disease Patients taking lipid lowering agents or isotretinoin or tofacitinib Patients taking nsaids, bets blockers, antimalarials, penicillamine, thiazides, ACEI, quinidine

Design outcomes

Primary

MeasureTime frame
Atherogenic index of plasma levels and cardiovascular risk categorization in Lichen planus patientsTimepoint: At baseline—

Secondary

MeasureTime frame
Lipid profile abnormalities, prevalence of dyslipidemia and correlation of AIP with clinical parameters like age, gender, disease durationTimepoint: At baseline or 0 weeks—

Countries

India

Contacts

Public ContactDr Prasanna Kumar R G

JJM Medical College

Drsugareddyreddy@gmail.com9448251468

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026